Differences

This shows you the differences between two versions of the page.

--- michael_kent_ranson [2022/07/26 00:09]
liam [Michael Kent Ranson]
+++ michael_kent_ranson [2023/04/23 06:13] (current)
liam
@@ Line 3: / Line 3: @@
 {{ ::michael-kent-ranson_source.jpeg?200|}}
-**Michael Kent Ranson** is a health economist. He is notable in the [[COVID-19 pandemic]] due to his role as a board member for [[gavi|Gavi, the Vaccine Alliance]].
+**Michael Kent Ranson** is a Canadian health economist. He is notable in the [[COVID-19 pandemic]] due to his role as a board member for [[gavi|Gavi, the Vaccine Alliance]].
 ===== Background =====
 ==== Education ====
-Ranson holds an MD from [[McMaster University]], an MPH from the [[Harvard School of Public Health]], and a DPhil in health economics and financing from the [[London School of Hygiene and Tropical Medicine]].((//Michael Kent Ranson.// (2021, October 22). Gavi, the Vaccine Alliance. https://archive.ph/sMv3m))
+Ranson holds an MD from [[McMaster University]], an MPH from the [[Harvard School of Public Health]], and a DPhil in health economics and financing from the [[London School of Hygiene and Tropical Medicine]].((//Michael Kent Ranson.// (2021, October 22). Gavi, the Vaccine Alliance. http://archive.today/2022.07.25-215508/https://www.gavi.org/governance/gavi-board/members/michael-kent-ranson))
 ===== Career =====
-Ranson has been a Senior Health Economist based in the World Bank office in Geneva, since 2014. He is the World Bank’s focal point for engagement with Gavi and COVAX, and has served as Gavi Board Alternate, and on the Gavi Programme and Policy Committee, since 2018. He is part of the team that developed a new mechanism that allows countries to use World Bank financing to purchase COVID-19 vaccines, beyond the fully donor-subsidised doses they are already receiving, through COVAX. He is co-chair of the Immunization Agenda 2030 Financial Sustainability working group.
+==== London School of Hygiene and Tropical Medicine ====
+Ranson researched, wrote and taught on health financing and system issues, first as a lecturer at the London School of Hygiene and Tropical Medicine (LSHTM), where he led a cluster randomised trial aimed at improving the equity impact of a community-based insurance program in [[india:Gujarat]], [[India]].
+==== World Health Organization ====
+Later, at the [[World Health Organization]], he supported health policy and systems research and led the secretariat for the First and Second [[Global Symposium on Health Systems Research]] under [[Health Systems Global]].((Milko, E., Wu, D., Neves, J., Neubecker, A. W., Lavis, J., & Ranson, M. K. (2014). //Second Global Symposium on Health Systems Research: a conference impact evaluation.// Health Policy and Planning, 30(5), 612–623. https://doi.org/10.1093/heapol/czu040))
+==== World Bank ====
+Ranson has been a Senior Health Economist based in the [[World Bank]] office in [[switzerland:Geneva]] since 2014. He is the World Bank’s focal point for engagement with [[Gavi]] and [[COVAX]], and has served as Gavi Board Alternate and on the Gavi Programme and Policy Committee since 2018.
+He is part of the team that developed a new mechanism that allows countries to use World Bank financing to purchase [[COVID-19 vaccines]], beyond the fully donor-subsidized doses they are already receiving, through COVAX. He is co-chair of the [[Immunization Agenda 2030]] Financial Sustainability working group.
+He also participated on the [[UHC2030]] Working Group on Sustainability, Transition from Aid and Health System Strengthening in 2017.((//First face to face meeting of the UHC2030 Working Group on Sustainability, Transition from Aid and Health System Strengthening.// (2017, March). UHC2030. https://web.archive.org/web/20210623044309/https://www.uhc2030.org/fileadmin/uploads/uhc2030/Documents/About_UHC2030/UHC2030_Working_Groups/2017_Transition_working_group_docs/Provisional_lst_of_participants_30-31_March_2017__1_.pdf))
+===== Other affiliations =====
-Prior to joining the World Bank, he researched, wrote and taught on health financing and system issues, first as a lecturer at the London School of Hygiene and Tropical Medicine (LSHTM), where he led a cluster randomised trial aimed at improving the equity impact of a community-based insurance program in Gujarat, India. Later, at the World Health Organization, he supported health policy and systems research and led the secretariat for the First and Second Global Symposia on Health Systems Research.
+  * [[Alliance for Health Policy and Systems Research]]
+  * [[Centre for Health Economics and Policy Analysis]]
+  * [[Harvard University]], Department of Health and Policy Management
+  * [[Health Economics and Systems Analysis Group]] (HESA)
+  * [[London School of Economics and Political Science]]
+  * [[McMaster Health Forum]]
+  * [[Michael DeGroote School of Medicine]], [[McMaster University]]
+  * [[Program in Policy Decision-Making]]
+  * [[Public Health Foundation of India]]
+  * [[Queen's University]]
+  * [[Royal Holloway, University of London]]
+  * [[University of British Columbia]]
+  * [[University of Cape Town]]
+  * [[University of Geneva]]
+  * [[University of Toronto]]